Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenerx Biopharmaceuticals RGRX

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.


Recent & Breaking News (OTCQB:RGRX)

Rodman & Renshaw Updates Analyst Report on RegeneRx Biopharmaceuticals, Inc. with Buy Rating

PR Newswire May 10, 2016

RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye

PR Newswire May 6, 2016

RegeneRx and ReGenTree Expand License for Dry Eye

PR Newswire April 28, 2016

RegeneRx to Receive EU Patent for Use of T?4 in Preventing And Treating Damage Associated with Reperfusion Injury

PR Newswire April 6, 2016

Rodman & Renshaw Initiates Coverage of RegeneRx Biopharmaceuticals, Inc. with Buy Rating

PR Newswire March 14, 2016

RegeneRx Meeting with Institutional Investors and Analysts At BIO CEO Conference

PR Newswire February 1, 2016

RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial

PR Newswire January 29, 2016

RegeneRx U.S. Joint Venture, ReGenTree, Launches Web Site

PR Newswire January 28, 2016

RegeneRx's TB4 Shown to Promote Regeneration and Repair of Damaged Central Nervous System Cells

PR Newswire January 27, 2016

RegeneRx Joint Venture Posts Results of Severe Dry Eye Trial On ClinicalTrials.gov

PR Newswire December 23, 2015

RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment

PR Newswire December 4, 2015

RegeneRx Analyst Report Update Issued by SeeThruEquity, LLC

PR Newswire October 28, 2015

SeeThruEquity Issues Update on RegeneRx Biopharmaceuticals, Inc. Highlighting Clinical Trial Progress

Accesswire October 28, 2015

SeeThruEquity Issues Update on RegeneRx Biopharmaceuticals, Inc. Highlighting Clinical Trial Progress

Accesswire October 28, 2015

RegeneRx Updates on Asian Ophthalmic Clinical Trials

PR Newswire October 23, 2015

RegeneRx Updates on U.S. Ophthalmic Clinical Trials

PR Newswire October 21, 2015

RegeneRx's TB4 Shown to Significantly Limit Brain Damage After Stroke by Upregulating microRNA-200a

PR Newswire October 20, 2015

RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial

PR Newswire September 30, 2015

RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259

PR Newswire September 21, 2015

RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259

PR Newswire September 16, 2015